Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency

Abstract Mutations in the homeobox gene SHOX cause SHOX deficiency, a condition with clinical manifestations ranging from short stature without dysmorphic signs to severe mesomelic skeletal dysplasia. In rare cases, individuals with SHOX deficiency are asymptomatic. To elucidate the factors that mod...

Full description

Saved in:
Bibliographic Details
Main Authors: Antonino Montalbano, Lonny Juergensen, Ralph Roeth, Birgit Weiss, Maki Fukami, Susanne Fricke‐Otto, Gerhard Binder, Tsutomu Ogata, Eva Decker, Gudrun Nuernberg, David Hassel, Gudrun A Rappold
Format: Article
Language:English
Published: Springer Nature 2016-11-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.15252/emmm.201606623
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343770892435456
author Antonino Montalbano
Lonny Juergensen
Ralph Roeth
Birgit Weiss
Maki Fukami
Susanne Fricke‐Otto
Gerhard Binder
Tsutomu Ogata
Eva Decker
Gudrun Nuernberg
David Hassel
Gudrun A Rappold
author_facet Antonino Montalbano
Lonny Juergensen
Ralph Roeth
Birgit Weiss
Maki Fukami
Susanne Fricke‐Otto
Gerhard Binder
Tsutomu Ogata
Eva Decker
Gudrun Nuernberg
David Hassel
Gudrun A Rappold
author_sort Antonino Montalbano
collection DOAJ
description Abstract Mutations in the homeobox gene SHOX cause SHOX deficiency, a condition with clinical manifestations ranging from short stature without dysmorphic signs to severe mesomelic skeletal dysplasia. In rare cases, individuals with SHOX deficiency are asymptomatic. To elucidate the factors that modify disease severity/penetrance, we studied a three‐generation family with SHOX deficiency. The variant p.Phe508Cys of the retinoic acid catabolizing enzyme CYP26C1 co‐segregated with the SHOX variant p.Val161Ala in the affected individuals, while the SHOX mutant alone was present in asymptomatic individuals. Two further cases with SHOX deficiency and damaging CYP26C1 variants were identified in a cohort of 68 individuals with LWD. The identified CYP26C1 variants affected its catabolic activity, leading to an increased level of retinoic acid. High levels of retinoic acid significantly decrease SHOX expression in human primary chondrocytes and zebrafish embryos. Individual morpholino knockdown of either gene shortens the pectoral fins, whereas depletion of both genes leads to a more severe phenotype. Together, our findings describe CYP26C1 as the first genetic modifier for SHOX deficiency.
format Article
id doaj-art-58e159e9c09d4bc3a1633d55a5311edb
institution Kabale University
issn 1757-4676
1757-4684
language English
publishDate 2016-11-01
publisher Springer Nature
record_format Article
series EMBO Molecular Medicine
spelling doaj-art-58e159e9c09d4bc3a1633d55a5311edb2025-08-20T03:42:52ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842016-11-018121455146910.15252/emmm.201606623Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiencyAntonino Montalbano0Lonny Juergensen1Ralph Roeth2Birgit Weiss3Maki Fukami4Susanne Fricke‐Otto5Gerhard Binder6Tsutomu Ogata7Eva Decker8Gudrun Nuernberg9David Hassel10Gudrun A Rappold11Department of Human Molecular Genetics, Heidelberg UniversityDepartment of Internal Medicine III ‐ Cardiology, Heidelberg University HospitalDepartment of Human Molecular Genetics, Heidelberg UniversityDepartment of Human Molecular Genetics, Heidelberg UniversityDepartment of Molecular Endocrinology, National Research Institute for Child Health and DevelopmentChildren's Hospital KrefeldChildren's Hospital, University of TübingenDepartment of Pediatrics, Hamamatsu University School of MedicineBioscientia Center for Human GeneticsCenter for Molecular MedicineDepartment of Internal Medicine III ‐ Cardiology, Heidelberg University HospitalDepartment of Human Molecular Genetics, Heidelberg UniversityAbstract Mutations in the homeobox gene SHOX cause SHOX deficiency, a condition with clinical manifestations ranging from short stature without dysmorphic signs to severe mesomelic skeletal dysplasia. In rare cases, individuals with SHOX deficiency are asymptomatic. To elucidate the factors that modify disease severity/penetrance, we studied a three‐generation family with SHOX deficiency. The variant p.Phe508Cys of the retinoic acid catabolizing enzyme CYP26C1 co‐segregated with the SHOX variant p.Val161Ala in the affected individuals, while the SHOX mutant alone was present in asymptomatic individuals. Two further cases with SHOX deficiency and damaging CYP26C1 variants were identified in a cohort of 68 individuals with LWD. The identified CYP26C1 variants affected its catabolic activity, leading to an increased level of retinoic acid. High levels of retinoic acid significantly decrease SHOX expression in human primary chondrocytes and zebrafish embryos. Individual morpholino knockdown of either gene shortens the pectoral fins, whereas depletion of both genes leads to a more severe phenotype. Together, our findings describe CYP26C1 as the first genetic modifier for SHOX deficiency.https://doi.org/10.15252/emmm.201606623clinical variabilitygenetic modifierslimb developmentretinoic acidskeletal dysplasia
spellingShingle Antonino Montalbano
Lonny Juergensen
Ralph Roeth
Birgit Weiss
Maki Fukami
Susanne Fricke‐Otto
Gerhard Binder
Tsutomu Ogata
Eva Decker
Gudrun Nuernberg
David Hassel
Gudrun A Rappold
Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency
EMBO Molecular Medicine
clinical variability
genetic modifiers
limb development
retinoic acid
skeletal dysplasia
title Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency
title_full Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency
title_fullStr Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency
title_full_unstemmed Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency
title_short Retinoic acid catabolizing enzyme CYP26C1 is a genetic modifier in SHOX deficiency
title_sort retinoic acid catabolizing enzyme cyp26c1 is a genetic modifier in shox deficiency
topic clinical variability
genetic modifiers
limb development
retinoic acid
skeletal dysplasia
url https://doi.org/10.15252/emmm.201606623
work_keys_str_mv AT antoninomontalbano retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT lonnyjuergensen retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT ralphroeth retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT birgitweiss retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT makifukami retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT susannefrickeotto retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT gerhardbinder retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT tsutomuogata retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT evadecker retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT gudrunnuernberg retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT davidhassel retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency
AT gudrunarappold retinoicacidcatabolizingenzymecyp26c1isageneticmodifierinshoxdeficiency